
Why Greenleaf?

A Trusted Partner
Greenleaf Health is a leading FDA regulatory consulting firm that provides strategic and technical guidance to pharmaceutical, biotechnology, and medical device companies researching, developing, and manufacturing innovative solutions to pressing global public health challenges.

Insight and Influence
Through their work at the FDA, Greenleaf experts directly influenced significant policy decisions and regulatory actions of recent decades.
Leading:
- The Centers for Devices and Biologics
- CDER’s Office of New Drugs and Office of Compliance
- The Office of Regulatory Affairs and its headquarters offices
- The Office of Combination Products
- FDA’s Europe Office
Designing, implementing, and guiding:
- New regulatory frameworks for emerging fields
- Global compliance and enforcement policy
- International science and regulatory policy efforts
- Emergency response measures

Invested in Your Success
Our unique expertise has helped companies navigate the complex FDA landscape for 15 years. Learn how Greenleaf’s teams work with clients to develop successful approaches to a range of regulatory scenarios.
Greenleaf Leadership
Greenleaf is led by a team of professionals who have distinguished themselves in both the public and private sectors. We are committed to serving our clients with extensive expertise and unwavering integrity.
-
Patrick Ronan
CEO, Greenleaf Health and Vice Chair, Validant Group -
John Taylor
President and Principal, Compliance and Regulatory Affairs -
Kathleen Sonntag
Chief Operating Officer -
Daniel Schultz, M.D., F.A.C.S.
Principal, Medical Devices and Combination Products -
John K. Jenkins, M.D.
Principal, Drug and Biological Products -
Robert J. Meyer, M.D.
Principal, Drug and Biological Products -
Karen Midthun, M.D.
Principal, Drug and Biological Products -
Sandra L. Kweder, M.D.
Principal, Drug and Biological Products -
David Elder
Principal, Regulatory Compliance -
Cynthia Schnedar
Principal, Regulatory Compliance -
Maura M. Norden, J.D.
Executive Vice President, Medical Devices and Combination Products and General Counsel -
Taryn Fritz Walpole
Chief of Staff
Executive Vice President, Regulatory Affairs
Services at a Glance
With our comprehensive services and the wealth of knowledge available through our subject experts and network of technical specialists, clients can rely on unmatched guidance throughout the regulatory process.
Drug & Biological Products
Strategic advice on therapeutic product development, regulatory review, and postmarket requirements, as well as pipeline review and FDA milestone meeting preparation

Greenleaf Health
Greenleaf’s comprehensive services and wealth of experience ensure that clients can count on expert guidance as they navigate complex regulatory challenges.
Devices & Combination Products
Insight and guidance throughout the regulatory process for medical devices and combination products, including premarket strategic planning, submissions, and FDA meetings and engagement
Quality & Compliance
Full-service quality and compliance support, from on-site and remote compliance assessments, remediation, and inspection readiness to clinical quality systems and supply chain optimization
Cell & Gene Therapy
Specialized assistance with FDA interactions and submissions to support development, review, manufacturing, quality, and compliance for cell and gene therapies
Litigation Support Services
Expert opinions and FDA regulatory knowledge to support litigators and their clients in disputes related to medical devices, drug and biological products, and product quality, manufacturing, and compliance
Advisory Services
Regulatory risk assessments for life science investors — based on extensive research and due diligence, informed by Greenleaf’s deep regulatory knowledge

Regulatory Policy Services
Support for stakeholders in communicating effectively about FDA regulatory policy issues and in understanding, implementing, and complying with the FDA’s regulatory programs

Digital Health
Strategic guidance in navigating and complying with the complex landscape of FDA regulations and policies related to digital health technologies
Greenleaf in Detail
To explore Greenleaf’s complete portfolio of capabilities and expert teams, view or download the PDFs below.